Fenofibrate
فنوفیبرات
❤️ Cardiovascular SystemFibrate
Market / country: 🇺🇸 USA
Tricor (US) · Lipanthyl (GB)
🧮 Dose calculator
Hyperlipidemia / heterozygous familial hypercholesterolemia · Regimen source: FDA Fenofibrate · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Severe renal impairment or dialysis; active liver disease; gallbladder disease; breastfeeding; hypersensitivity. FDA Fenofibrate · 4
Formulations
- 54 mg tablet — tablet 🇺🇸 USA FDA Fenofibrate · 3
- 160 mg tablet — tablet 🇺🇸 USA FDA Fenofibrate · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Fenofibrate · 8.1
“Risk Summary Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”
- 🤱 BreastfeedingContraindicated
Label: contraindicated while breastfeeding. FDA Fenofibrate · 4
“… arnings and Precautions (5.2) ] . patients with preexisting gallbladder disease [see Warnings and Precautions (5.5) ] . nursing mothers [see Use in Specific Populations (8.2) ] . patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions (5.9) ] .”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Fenofibrate · 8.4
“Safety and effectiveness have not been established in pediatric patients.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Fenofibrate · 8.5
“Since elderly patients have a higher incidence of renal impairment, dose selection for the elderly should be made on the basis of renal function [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ] .”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA207803
- DailyMed (FDA label)FDA Fenofibrate
- MedlinePlus (NIH)Fenofibrate
- WHO ATC/DDDC10AB05
- Darooyab (Iran)Fenofibrate
🇮🇷 Registered in Iran Darooyab · G-1680/Fenofibrate
Dosage forms with Iranian generic codes, per Darooyab.
- 10932 · FENOFIBRATE 100MG CAP · کپسول فنوفیبرات ۱۰۰ میلیگرم
- 05992 · FENOFIBRATE 200MG CAP · کپسول فنوفیبرات ۲۰۰ میلیگرم
- 08012 · FENOFIBRATE 67MG CAP · کپسول فنوفیبرات ۶۷ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Fenofibrate · 3FDA Fenofibrate · 2.2FDA Fenofibrate · 2.3FDA Fenofibrate · 2.4FDA Fenofibrate · 2.1FDA Fenofibrate · 8.4FDA Fenofibrate · 4FDA Fenofibrate · 8.1FDA Fenofibrate · 8.5FDA Fenofibrate · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1680/Fenofibrate
- Clinical review⚠ Unverified